A detailed history of Neo Ivy Capital Management transactions in Pfizer Inc stock. As of the latest transaction made, Neo Ivy Capital Management holds 5,668 shares of PFE stock, worth $168,112. This represents 0.03% of its overall portfolio holdings.

Number of Shares
5,668
Holding current value
$168,112
% of portfolio
0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$25.26 - $29.6 $143,173 - $167,772
5,668 New
5,668 $158,000
Q3 2023

Nov 29, 2023

BUY
$32.09 - $37.51 $620,235 - $724,993
19,328 New
19,328 $641,000
Q2 2022

Aug 16, 2022

SELL
$46.53 - $55.17 $285,042 - $337,971
-6,126 Reduced 79.77%
1,554 $81,000
Q1 2022

May 16, 2022

BUY
$45.75 - $56.69 $351,360 - $435,379
7,680 New
7,680 $398,000
Q4 2021

Feb 15, 2022

SELL
$41.32 - $61.25 $1.02 Million - $1.51 Million
-24,668 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$39.25 - $50.42 $231,300 - $297,125
5,893 Added 31.39%
24,668 $807,000
Q2 2021

Aug 16, 2021

BUY
$35.91 - $40.68 $504,355 - $571,350
14,045 Added 296.93%
18,775 $735,000
Q1 2021

Oct 07, 2021

BUY
$33.49 - $37.77 $158,407 - $178,652
4,730 New
4,730 $171,000
Q4 2020

Feb 16, 2021

SELL
$33.47 - $42.56 $608,317 - $773,528
-18,175 Closed
0 $0
Q3 2020

Nov 17, 2020

BUY
$31.75 - $37.25 $577,056 - $677,018
18,175 New
18,175 $667,000
Q2 2020

Aug 17, 2020

SELL
$30.12 - $36.54 $743,000 - $901,368
-24,668 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$30.12 - $36.54 $743,000 - $901,368
24,668 New
24,668 $807,000
Q2 2019

Aug 15, 2019

SELL
$36.98 - $41.52 $177,171 - $198,922
-4,791 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$37.5 - $41.2 $179,662 - $197,389
4,791 New
4,791 $203,000

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $166B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Neo Ivy Capital Management Portfolio

Follow Neo Ivy Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Neo Ivy Capital Management with notifications on news.